Tujuan penelitian ini adalah untuk melihat hubungan antara serum Prostate Specific Antigen ( PSA ) Prostate cancer is now the most common cancer and the second leading cause of death from cancer among men in the USA and Europe .
With the ageing of the population, the public health burden of prostate cancer will certainly increase in the future. 1 Diagnostic and therapeutic protocols are certainly needed in managing patient to reduce costs and preserve quality. 2 Until recently, the standard staging evaluation for a patient with newly diagnosed, biopsy-proved prostate cancer included digital rectal examination, serum Prostate Specific Antigen ( PSA ) determination and bone scan examination. 3 The primary objective of clinical staging of prostate cancer is to ensure that the patient will receive the most appropriate treatment modality. 1 Chybowsky et al suggested that serum PSA has been shown to correlate directly with clinical stage. On the other hand, clinical tumor stage, tumor grade and serum PSA correlated positively with bone scan findings. 4 Several investigators concluded that a low serum PSA concentration rarely had skeletal metastases, so that a routine bone scan in a previously untreated prostate cancer patients with a low serum PSA concentration (< 10 ng/ml) might not be necessary. 1, 3, 4, 5 At the Division of Urology, Cipto Mangunkusumo Hospital and Dharmais National Cancer Center Jakarta, bone scan is still routinely performed to all newly diagnosed prostate cancer.
The objective of this study is to assess the relation between serum PSA, clinical tumor stage, tumor grade and bone scan result in an attempt to seek the ability of serum PSA to predict bone metastases in newly diagnosed prostate cancer patients.
METHODS
We conducted a retrospective analysis on clinical files from prostate cancer patients which were diagnosed at the Division of Urology, Cipto Mangunkusumo Hospital and Dharmais National Cancer Center Jakarta between January 1995 and December 2003. Patients on which initial serum PSA were obtained after urethral manipulation (catheterization, Transurethral Resection of the Prostate / TUR-P) or after receiving therapy (either surgery, radiation or hormonal) were excluded.
Clinical data on tumor stage, grade, serum PSA and bone scan results were obtained from the medical records. Clinical tumor stage was categorized according to the TNM staging system (American Joint Committee on Cancer, 2002). 6 Histological grades were determined as either G1 (well differentiated), G2 (moderately differentiated) or G3-4 (poorly differentiated / undifferentiated) according to WHO classification. 7 All bone scans were performed using 99m Technetium ( 99m Tc) -methylene diphosphonate and interpreted as either positive or negative.
The serum PSA distribution for the bone scan groups was compared using the Mann-Whitney U test. The relation between serum PSA, clinical tumor stage, tumor grade and bone scan results were analyzed using Chi Square test, with p < 0.05 considered to indicate statistical significance. Logistic regression analysis with the likelihood ratio Chi Square test was also used to define the correlation between each variable ( serum PSA, clinical tumor stage and tumor grade ) and bone scan results. This technique was used to test univariate variables as well as multivariate combinations of variables to determine the best model for prediction of bone metastases. Finally, Receiver Operating Characteristic (ROC) curves were determined to evaluate the efficiency of PSA, clinical tumor stage and tumor grade for the diagnosis of bone metastases.
RESULTS
Between January 1995 and December 2003, 286 histopathological-proved prostate cancer patients were registered in our institutions. We excluded 183 patients from the study because their serum PSA were obtained after urethral manipulation or after receiving therapy. Of 103 patients who were included in this investigation, the mean age was 68.13  9.22 years ( range 40 to 92 years ). Serum PSA ranged from 0.20 -4663.00 ng/ml ( median 52.10 ng/ml ).
Of 103 patients who were included in this study, 61 patients ( 59.2% ) had a positive bone scan and 42 patients ( 40.8% ) had a negative bone scan with mean PSA value 471.13  853.34 ng/ml and 61.00  124.47 ng/ml respectively ( p = 0.000 ) ( Figure 1 ).
Using Chi Square test, the relation between serum PSA, clinical tumor stage, tumor grade and bone scan results were significantly different ( p < 0.05 ) ( Table 2 ). The most important prognostic indicator at initial diagnosis is the presence or absence of bone metastases. 11 The most sensitive technique for detecting bone metastases is bone scan, 1, 4, 9, 11, 12 which was developed in 1963 and has false negative scans less than 1%. 4 It is superior to clinical evaluation and bone radiographs, as well as measurement of serum Alkaline Phosphatase (ALP) and Prostatic Acid Phosphatase (PAP) level. 4, 13 Based on these reasons, bone scan is performed routinely in determining clinical stage for all newly diagnosed prostate cancer. 11, 12 Although extremely accurate in evaluating the skeleton for metastases disease, the radionuclide bone scan is a costly diagnostic study. 4 More over, at initial presentation, only approximately 20 -25 % of men with prostate cancer have bone metastases. 12 Because serum PSA levels are proportional to tumor volume and clinical stage, minimal elevations in serum PSA in newly diagnosed patients with prostate cancer may identify a subgroup of patients with a negligible risk for positive bone scans. 1, 9 This study revealed that bone scan-positive patients had a statistically higher level of PSA than the bone scan-negative patients (p < 0.05) and the risk of having a positive bone scan increased with advancing serum PSA level, clinical tumor stage and grade (p < 0.05 respectively).
Chybowsky et al, 4 who conducted a retrospective study in Mayo Clinic, involving 521 newly diagnosed, untreated prostate cancer patients; concluded that serum PSA, clinical tumor stage and grade correlated positively with the incidence of a positive bone scan. Gleave et al 9 from Vancouver Hospital and Health Sciences Center reported that the risk of having a positive bone scan increased with increasing serum PSA levels and advancing tumor stage and grade. Other investigators such as Lorete et al 14 and Morote et al 15 recommended that Bone Alkaline Phosphatase (BAP) could be a complementary marker to PSA in the diagnosis of bone metastases in patients with prostate cancer.
Oesterling et al has successfully proved that serum PSA is the most accurate and reliable predictor of the bone scan findings. 3 That matter has also been proved in this study. PSA was the best single predictor bone scan results, followed by tumor stage and tumor grade (Table 3) . ROC curves also revealed that serum PSA has Area Under Curve ( AUC ) = 0.812, higher than either clinical tumor stage ( 0.733 ) or grade (0.650) (Figure 2 ).
In our study, the combinations of serum PSA, clinical tumor stage and tumor grade more accurately predicted bone scan results than any single variable, with the combination of all 3 variables providing the most statistically significant prediction (Table 4) . This condition was analogous to the 'Partin Tables' which using the combination of serum PSA, clinical stage and Gleason score to predict final pathological stage in prostate cancer patients. 16, 17 However, Gleason grading of the prostate biopsy alone remains a poor predictor of pathological outcome. 18 Although serum PSA is the best predictor in determining bone scan result, serum PSA alone at different cutoff points (< 10 ng/ml, < 20 ng/ml and < 50 ng/ml respectively ) have low negative predictive value (65% -78%). On the other hand , if serum PSA is combined with clinical tumor stage (T) and grade (G), it will have the best ability to predict a negative bone scan finding (Table 5 ). This study revealed that bone scans were positive in 5 of 19 patients with PSA level < 10 ng/ml. None of 8 patients with PSA level < 10 ng/ml, clinical tumor stage T1 or 2 and tumor grade 1 or 2 had a positive bone scan (negative predictive value 100%).
Several studies reported that routine bone scan examination was not necessary in patients with newly diagnosed, untreated prostate cancer who had a low serum PSA (< 10 ng/ml). 1, 3, 4, 19, 20 Kosuda et al, in a multicenter retrospective study in Japan, suggested that baseline bone scans could be eliminated in patients with newly diagnosed prostate cancer who had serum PSA level  10 ng/ml or Gleason grade  2. 5 Gleave et al also concluded that bone scans were indicated when PSA levels were above 10 ng/ml, or with T3 or poorly differentiated disease. There is no bone metastases lesion detected from bone scan results of newly diagnosed prostate cancer patients at our institutions with serum PSA level < 10 ng/ml, T1 or 2 and grade 1 or 2, so that routine bone scan examination may not be necessary as a part of determining clinical stage in this group of patients.
